AIRC IG 2018 (ID 21939): Personalized Therapy of Metastatic Thyroid Cancer — Biological Characterization and Optimization With ¹²⁴I PET Dosimetry: A Two-Center, Single-Arm, Phase II Prospective Study
Phase: Phase II-III clinical trials
Principal Investigator: Dott. Maccauro Marco
Main Facility: Medicina Nucleare
Drug: Iodine-124 (for PET imaging and dosimetry)
Iodine-131 (for targeted)
Pathologies: Other
ClinicalTrials.gov: Read more about clinical trials
This is a two-center, prospective,single-arm Phase II study aimed at optimizing personalized treatment strategies for patients with metastatic thyroid cancer through advanced imaging and dosimetry.
The study evaluates the use of an experimental diagnostic radiopharmaceutical, Iodine-124 (¹²⁴I), combined with positron emission tomography (PET) imaging to perform patient-specific dosimetry. This approach enables precise quantification of iodine uptake in metastatic lesions, allowing clinicians to tailor subsequent therapeutic dosing with radioiodine (¹³¹I).
Key objectives include improving treatment efficacy, minimizing toxicity, and enhancing patient selection for radioiodine therapy by integrating biological characterization with quantitative imaging.
Last update: 20/04/2026